Publications

  1. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Jul 16 Epub 2022 July 16
    View PubMed
  2. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022 Jul 14; 140 (2):112-120
    View PubMed
  3. Wang Z, Yan H, Boysen JC, Secreto CR, Tschumper RC, Ali D, Guo Q, Zhong J, Zhou J, Gan H, Yu C, Jelinek DF, Slager SL, Parikh SA, Braggio E, Kay NE. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer J. 2022 Jul 1; 12 (7):99 Epub 2022 July 01
    View PubMed
  4. Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, Rabe KG, Vachon CM, Lesnick CE, Call TG, Olson JE, Cerhan JR, Kay NE, Hanson CA, Shanafelt TD, Slager SL. Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia. 2022 May; 36 (5):1404-1407 Epub 2022 Feb 15
    View PubMed
  5. Wang H, Tian S, Zhao Q, Blumenschein W, Yearley JH, Secreto CR, Sinha S, Call TG, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, Shi M, Van Dyke DL, Kay NE, Slager SL, Braggio E, Yan H, Ding W. Differential transcriptomic profiling in ibrutinib-naive versus ibrutinib-resistant Richter syndrome. Hematol Oncol 2022 Apr; 40 (2):302-306 Epub 2021 Dec 03
    View PubMed
  6. Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology. 2022 Jan; 75 (1):43-58 Epub 2021 Dec 12
    View PubMed
  7. Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia. 2022 Jan; 36 (1):119-125 Epub 2021 July 20
    View PubMed
  8. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021 Dec 30; 138 (26):2810-2827
    View PubMed
  9. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Schwager SM, Lesnick CE, Kleinstern G, Van Dyke D, Hanson CA, Braggio E, Slager SL, Shanafelt TD. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021 Jul 15; 138 (2):149-159
    View PubMed
  10. Vaisitti T, Arruga F, Vitale N, Lee TT, Ko M, Chadburn A, Braggio E, Di Napoli A, Iannello A, Allan JN, Miller LL, Lannutti BJ, Furman RR, Jessen KA, Deaglio S. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17; 137 (24):3365-3377
    View PubMed
  11. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
  12. Slager SL, Lanasa MC, Marti GE, Achenbach SJ, Camp NJ, Abbasi F, Kay NE, Vachon CM, Cerhan JR, Johnston JB, Call TG, Rabe KG, Kleinstern G, Boddicker NJ, Norman AD, Parikh SA, Leis JF, Banerji V, Brander DM, Glenn M, Ferrajoli A, Curtin K, Braggio E, Shanafelt TD, McMaster ML, Weinberg JB, Hanson CA, Caporaso NE. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood. 2021 Apr 15; 137 (15):2046-2056
    View PubMed
  13. Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021 Apr 7; 29 (4):1529-1540 Epub 2021 Jan 01
    View PubMed
  14. Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2 (1):54-69 Epub 2020 Dec 03
    View PubMed
  15. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
  16. Shi CX, Zhu YX, Bruins LA, Bonolo de Campos C, Stewart W, Braggio E, Stewart AK. Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. Mol Cancer Res. 2020 Oct; 18 (10):1453-1464 Epub 2020 June 19
    View PubMed
  17. Yan H, Tian S, Kleinstern G, Wang Z, Lee JH, Boddicker NJ, Cerhan JR, Kay NE, Braggio E, Slager SL. Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Hum Mol Genet. 2020 Sep 29; 29 (16):2761-2774
    View PubMed
  18. Kleinstern G, O'Brien DR, Li X, Tian S, Kabat BF, Rabe KG, Norman AD, Yan H, Vachon CM, Boddicker NJ, Call TG, Parikh SA, Bruins L, Bonolo de Campos C, Leis JF, Shanafelt TD, Ding W, Cerhan JR, Kay NE, Slager SL, Braggio E. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. Am J Hematol. 2020 Aug; 95 (8):906-917 Epub 2020 May 07
    View PubMed
  19. Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, Riggs DL, Welsh SJ, Meermeier EW, Kumar SK, Braggio E, Bergsagel PL. Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020 Jul; 1 (1):68-81
    View PubMed
  20. de Campos CB, Zhu YX, Sepetov N, Romanov S, Bruins LA, Shi CX, Stein CK, Petit JL, Polito AN, Sharik ME, Meermeier EW, Ahmann GJ, Armenta IDL, Kruse J, Bergsagel PL, Chesi M, Meurice N, Braggio E, Stewart AK. Identification of PIKfyve kinase as a target in multiple myeloma. Haematologica. 2020 Jun; 105(6):1641-1649. Epub 2019 Oct 03.
    View PubMed
  21. Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol. 2020 Jun; 85 (6):1063-1078 Epub 2020 May 21
    View PubMed
  22. Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020 May 11; 10 (5):54
    View PubMed
  23. Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Via MD, Sanchez R, Bruins L, Demler T, Muller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stuhmer T, Kortum KM. IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica 2020 May; 105 (5):e237-e241 Epub 2019 Sept 26
    View PubMed
  24. Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka YE, Guerriero JL, Goldman M, Van Allen EM, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May; 1 (5):493-506 Epub 2020 Apr 27
    View PubMed
  25. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
  26. Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortum KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL, MMRF CoMMpass Network. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020 Jan; 34 (1):322-326 Epub 2019 Aug 22
    View PubMed
  27. Smadbeck J, Peterson JF, Pearce KE, Pitel BA, Figueroa AL, Timm M, Jevremovic D, Shi M, Stewart AK, Braggio E, Riggs DL, Bergsagel PL, Vasmatzis G, Kearney HM, Hoppman NL, Ketterling RP, Kumar S, Rajkumar SV, Greipp PT, Baughn LB. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer J. 2019 Dec 16; 9 (12):103
    View PubMed
  28. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019 Aug 1; 381 (5):432-443
    View PubMed
  29. Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia 2019 Aug; 33 (8):2111-2115 Epub 2019 Mar 14
    View PubMed
  30. Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. J Oncol Pharm Pract. 2019 Jun; 25 (4):998-1002 Epub 2018 Apr 24
    View PubMed
  31. Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. Am J Hematol. 2019 Mar; 94 (3):338-345 Epub 2019 Jan 08
    View PubMed
  32. Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsagel PL, Stewart AK. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019 Feb 11; 9 (2):19
    View PubMed
  33. Barrio S, Stuhmer T, Da-Via M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortum KM. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019 Feb; 33 (2):447-456 Epub 2018 July 19
    View PubMed
  34. Ruiz-Heredia Y, Sanchez-Vega B, Onecha E, Barrio S, Alonso R, Martinez-Avila JC, Cuenca I, Agirre X, Braggio E, Hernandez MT, Martinez R, Rosinol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Blade J, Mateos MV, Kortum KM, Stewart K, Garcia-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica 2018 Nov; 103 (11):e544-e548 Epub 2018 June 28
    View PubMed
  35. Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR, Braggio E, Maurer MJ, Feldman AL, Witzig TE, Slager SL, Ansell SM, Cerhan JR, Novak AJ. Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer J. 2018 Oct 9; 8 (10):97 Epub 2018 Oct 09
    View PubMed
  36. Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018 Aug; 97 (8):1453-1462 Epub 2018 Apr 06
    View PubMed
  37. Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamo A, Tam W, Chadburn A, Furman RR, Deaglio S. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Res. 2018 Jul 1; 78 (13):3413-3420 Epub 2018 May 07
    View PubMed
  38. Barrio S, DaVia M, Bruins L, Stuhmer T, Steinbrunn T, Bittrich M, Einsele H, Stewart AK, Braggio E, Kortum KM. Protocol for M(3)P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma. Methods Mol Biol. 2018; 1792:117-128
    View PubMed
  39. Ayres-Silva JP, Bonamino MH, Gouveia ME, Monte-Mor BCR, Coutinho DF, Daumas AH, Solza C, Braggio E, Zalcberg IR. Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature. Front Oncol. 2018; 8:32 Epub 2018 Feb 19
    View PubMed
  40. Shi CX, Kortum KM, Zhu YX, Bruins LA, Jedlowski P, Votruba PG, Luo M, Stewart RA, Ahmann J, Braggio E, Stewart AK. CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. Mol Cancer Ther. 2017 Dec; 16 (12):2862-2870 Epub 2017 Sept 27
    View PubMed
  41. Gonzalez-Calle V, Keane N, Braggio E, Fonseca R. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clin Lymphoma Myeloma Leuk. 2017 Oct; 17 (10):621-630 Epub 2017 June 23
    View PubMed
  42. Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S, Russell SJ, Stewart AK, MMRF CoMMpass Network. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017 Sep 22; 7 (9):e612 Epub 2017 Sept 22
    View PubMed
  43. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  44. Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortum KM, Luo M, Ahmann JM, Braggio E, Stewart AK. Loss of FAM46C Promotes Cell Survival in Myeloma. Cancer Res. 2017 Aug 15; 77 (16):4317-4327 Epub 2017 June 15
    View PubMed
  45. Fonseca R, Cesarman-Maus G, Braggio E. Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. J Clin Oncol 2017 Jul 1; 35 (19):2217-2218 Epub 2017 May 08
    View PubMed
  46. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
    View PubMed
  47. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 1; 77 (7):1510-1541
    View PubMed
  48. Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 2017 Feb 23; 129 (8):991-1007 Epub 2016 Dec 27
    View PubMed
  49. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017 Jan; 31 (1):170-176 Epub 2016 June 14
    View PubMed
  50. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96 (1):51-55 Epub 2016 Oct 12
    View PubMed
  51. Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016 Sep 1; 128 (9):1226-33 Epub 2016 July 25
    View PubMed
  52. Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016 Feb 26; 6:e397
    View PubMed
  53. Segges P, Braggio E, Minnicelli C, Hassan R, Zalcberg IR, Maiolino A. Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context. Braz J Med Biol Res. 2016; 49 (5):e5034 Epub 2016 Apr 08
    View PubMed
  54. Kapoor P, Ansell SM, Braggio E. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. Cancer Treat Res. 2016; 169:321-361.
    View PubMed
  55. Braggio E, Kortum KM, Stewart AK. SnapShot: Multiple Myeloma. Cancer Cell. 2015 Nov 9; 28 (5):678-678.e1
    View PubMed
  56. Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O'Neill BP. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015 Sep 1; 21 (17):3986-94 Epub 2015 May 19
    View PubMed
  57. Shi CX, Kortum KM, Zhu YX, Jedlowski P, Bruins L, Braggio E, Stewart AK. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica 2015 Aug; 100 (8):e315-7 Epub 2015 May 14
    View PubMed
  58. Kortum KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015 Jul; 94 (7):1205-11 Epub 2015 Mar 07
    View PubMed
  59. Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 2015 May; 169 (3):445-8 Epub 2014 Nov 10
    View PubMed
  60. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol. 2015 Feb; 168 (4):507-10 Epub 2014 Oct 10
    View PubMed
  61. Zhu YX, Yin H, Bruins LA, Shi CX, Jedlowski P, Aziz M, Sereduk C, Kortuem KM, Schmidt JE, Champion M, Braggio E, Keith Stewart A. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood. 2015 Jan 15; 125 (3):483-91 Epub 2014 Nov 13
    View PubMed
  62. Ojha J, Ayres J, Secreto C, Tschumper R, Rabe K, Van Dyke D, Slager S, Shanafelt T, Fonseca R, Kay NE, Braggio E. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 2015 Jan 15; 125 (3):492-8 Epub 2014 Nov 06
    View PubMed
  63. Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, Slager S, Fonseca R, Shanafelt T, Kay N, Braggio E. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 2014 Dec; 28 (12):2395-8 Epub 2014 July 18
    View PubMed
  64. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014 Aug; 28 (8):1657-65 Epub 2014 Jan 23
    View PubMed
  65. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014 Jul 24; 124 (4):536-45 Epub 2014 June 09
    View PubMed
  66. Patrick O'Neill B, Braggio E, O'Neill BP, Van Wier S, Ojha J, McPhail E, Asmann Y, Egan J, Ayres da Silva J, Schiff D, Lopes MB, Valdez R, Tibes R, Eckloff B, Stewart AK, Fonseca R. Genome-wide analysis uncovers recurrent alterations in primary central nervous system lymphomas (pcnsl). Neuro Oncol. 2014 Jul; 16 Suppl 3:iii43.
    View PubMed
  67. Cesarman-Maus G, Braggio E, Lome-Maldonado C, Morales-Leyte AL, Fonseca R. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res. 2014 Apr; 133 (4):606-9 Epub 2014 Jan 23
    View PubMed
  68. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J. 2014 Feb 14; 4:e183
    View PubMed
  69. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014 Jan; 38 (1):23-8 Epub 2013 Sept 05
    View PubMed
  70. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013 Dec; 27 (12):2357-65 Epub 2013 June 11
    View PubMed
  71. Monge J, Braggio E, Ansell SM. Genetic factors and pathogenesis of Waldenstrom's macroglobulinemia. Curr Oncol Rep. 2013 Oct; 15 (5):450-6
    View PubMed
  72. Jimenez-Zepeda VH, Braggio E, Fonseca R. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):552-8. Epub 2013 Jul 12.
    View PubMed
  73. Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013 Oct; 98(10):1586-92. Epub 2013 May 28.
    View PubMed
  74. Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):467-76.
    View PubMed
  75. Braggio E, Egan JB, Fonseca R, Stewart AK. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 2013 Jul 19; 3:e127 Epub 2013 July 19
    View PubMed
  76. Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013 Apr 18; 121(16):3147-52. Epub 2013 Feb 19.
    View PubMed
  77. Braggio E, Fonseca R. Genomic abnormalities of Waldenstrom macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13 (2):198-201 Epub 2013 Mar 09
    View PubMed
  78. Braggio E, Albarracin Garramuno F. [Genetic tools for risk-stratification in multiple myeloma]. Medicina (B Aires). 2013; 73(4):369-75.
    View PubMed
  79. Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS One. 2013; 8(6):e66982. Epub 2013 Jun 13.
    View PubMed
  80. Braggio E, Fonseca R, Kay NE. CGH protocols: chronic lymphocytic leukemia. Methods Mol Biol. 2013; 973:87-98.
    View PubMed
  81. Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, Ziesmer S, Secreto F, Fonseca R, Gupta M, Law M, Witzig TE, Dyer MJ, Dogan A, Cerhan JR, Novak AJ. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood. 2012 Nov 8; 120 (19):3949-57 Epub 2012 Sept 10
    View PubMed
  82. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012 Sep 13; 120 (11):2280-9 Epub 2012 Aug 01
    View PubMed
  83. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica. 2012 Sep; 97 (9):1281-90 Epub 2012 July 06
    View PubMed
  84. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012 Aug 2; 120 (5):1060-6 Epub 2012 Apr 23
    View PubMed
  85. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012 Aug 2; 120 (5):1067-76 Epub 2012 Apr 12
    View PubMed
  86. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia. 2012 Jul; 26(7):1671-4. Epub 2012 Feb 15.
    View PubMed
  87. Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012 Jul; 26 (7):1698-701 Epub 2012 Jan 20
    View PubMed
  88. Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR, Miranda EC, Quero AA, Peres AL, Barros JC, Tanaka P, Magalhães RP, Rego EM, Lorand-Metze I, Lima CS, Renault IZ, Braggio E, Chiattone C, Nucci M, de Souza CA, for the Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH). Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol.2012;
  89. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012 May; 25 (5):651-60 Epub 2012 Feb 03
    View PubMed
  90. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012 Apr; 17 Suppl 1:S177-80.
    View PubMed
  91. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012 Mar 22; 119 (12):2863-72 Epub 2012 Jan 20
    View PubMed
  92. Watkins AJ, Hamoudi RA, Zeng N, Yan Q, Huang Y, Liu H, Zhang J, Braggio E, Fonseca R, de Leval, Isaacson PG, Wotherspoon A, McPhail ED, Dogan A, Du MQ. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 2012; 7(9):e44997. Epub 2012 Sep 13.
    View PubMed
  93. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7 (10):e43192 Epub 2012 Oct 10
    View PubMed
  94. Braggio E, Kay N, Van Wier S, Tschumper RC, Smoley SA, Eckel-Passow JE, Sassoon T, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Blood. 2011 Nov 18; 118(21):1223-4.
  95. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011 Nov 3; 118 (18):4771-9 Epub 2011 Aug 22
    View PubMed
  96. Segges P, Braggio E. Genetics markers used for risk stratification in multiple myeloma. Genet Res Int.2011;
  97. Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology? Eur J Haematol. 2011 Jul; 87(1):20-7.
    View PubMed
  98. Braggio E, McPhail ER, Macon W, Lopes MB, Schiff D, Law M, Fink S, Sprau D, Giannini C, Dogan A, Fonseca R, O'Neill BP. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011 Jul 1; 17 (13):4245-53 Epub 2011 May 11
    View PubMed
  99. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, Morice WG, Gertz MA, Ansell SM. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood. 2011 May 12; 117 (19):e190-7 Epub 2011 Mar 17
    View PubMed
  100. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011 Apr 7; 117 (14):3847-57 Epub 2011 Feb 02
    View PubMed
  101. Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S, Manier S, Soenen V, Nibourel O, Duthilleul P, Fonseca R, Leleu X. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):106-8.
    View PubMed
  102. Fonseca R, Braggio E. The use of genetic markers and signatures in multiple myeloma risk stratification. ASCO Educational Book. 2011.
  103. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203 (2):161-8
    View PubMed
  104. Ansell SM, Akasaka T, Manske M, Price-troska T, Ziesmer S, Braggio E, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJS, Dogan A, Novak AJ. A newly identified translocation t(X;14)(p11;q32) In MALT lymphoma involving IGHS and GPR34 reveals a novel role for GPR34 in cell growth and tumor development. Blood. 2010 Nov 19; 116(21):833-4.
  105. Braggio E, O'Neill BP, Macon W, Lopes MB, Schiff D, Fonseca R. Characterization of the Copy Number Changes In Primary CNS Lymphomas (PCNSL) by High Resolution Array Based Comparative Genomic Hybridization. Blood. 2010 Nov 19; 116(21):438-9.
  106. Braggio E, Braggio Dde A, Small IA, Lopes LF, Valadao M, Gouveia ME, Moreira Ados S, Linhares E, Romano S, Bacchi CE, Renault IZ, Guimaraes DP, Ferreira CG. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Res. 2010 Jun; 30(6):2407-14.
    View PubMed
  107. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010 Feb 25; 115 (8):1594-604 Epub 2009 Dec 07
    View PubMed
  108. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M, Renault IZ. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol. 2010 Jan; 91(1):87-96.
    View PubMed
  109. Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009 Nov 20; 27(33):e194-7. Epub 2009 Oct 05.
    View PubMed
  110. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69 (8):3579-88 Epub 2009 Apr 07
    View PubMed
  111. Conte G, Braggio E, Figueroa G, Fonseca R. Genetic markers as prognostic factors in multiple myeloma [Spanish]. Rev Med Chil. 2009 Apr; 137(4):552-8.
  112. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9 (1):39-42
    View PubMed
  113. Abreu PA, Dellamora-Ortiz G, Leao-Ferreira LR, Gouveia M, Braggio E, Zalcberg I, Santos DO, Bourguinhon S, Cabral LM, Rodrigues CR, Castro HC. DNA methylation: a promising target for the twenty-first century. Expert Opin Ther Targets. 2008 Aug; 12(8):1035-47.
    View PubMed
  114. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008 Feb 1; 111 (3):1603-9 Epub 2007 Nov 15
    View PubMed
  115. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007 Aug; 12 (2):131-44
    View PubMed
  116. Braggio E, Zalcberg I. Molecular abnormalities in multiple myeloma. Brazilian Journal of Hematology. 2007; 29(1):12-8.
  117. Hassan R, Bonamino MH, Braggio E, Lobo AM, Seuanez HN, Tabak DG, Zalcberg IR. A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia. Eur J Haematol. 2004 Sep; 73(3):156-61.
    View PubMed
  118. Braggio E, Bonvicino CR, Vargas FR, Ferman S, Eisenberg AL, Seuanez HN. Identification of three novel RB1 mutations in Brazilian patients with retinoblastoma by "exon by exon" PCR mediated SSCP analysis. J Clin Pathol. 2004 Jun; 57(6):585-90.
    View PubMed
  119. Braggio E, Bonvicino CR. Molecular analysis in the genus thrichomys (rodentia, echimyidae). Journal of Mammalogy. 2004; 85(2):316-20.
  120. Bovicino CR, Penna-Firme V, Braggio E. Molecular evidences of the taxonomic status of coendou and sphiggurus (rodentia, hystricognathi). Journal of Mammalogy. 2002; 83(4):1071-6.
  121. Braggio E, Gimenez MD, Contreras JR, Justo E, Bidau CJ. Karyotypic variation in populations of ctenomys (rodentia, ctenomyidae) from La Pampa Province (Argentina). Caryologia. 1999; 52(3):131-40.